Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Get Free Report)'s share price was up 6.7% on Wednesday . The company traded as high as $0.55 and last traded at $0.49. Approximately 59,902,238 shares changed hands during trading, a decline of 42% from the average daily volume of 103,490,164 shares. The stock had previously closed at $0.46.
Wall Street Analyst Weigh In
Separately, StockNews.com initiated coverage on Tonix Pharmaceuticals in a research report on Sunday. They issued a "hold" rating on the stock.
View Our Latest Stock Analysis on TNXP
Tonix Pharmaceuticals Stock Down 54.7 %
The firm has a 50-day moving average price of $0.30 and a two-hundred day moving average price of $0.27. The company has a market capitalization of $36.26 million, a P/E ratio of 0.00 and a beta of 2.07. The company has a quick ratio of 2.81, a current ratio of 3.33 and a debt-to-equity ratio of 0.07.
Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The firm had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. Equities research analysts anticipate that Tonix Pharmaceuticals Holding Corp. will post -17.63 EPS for the current fiscal year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Tonix Pharmaceuticals stock. PFG Investments LLC acquired a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 218,003 shares of the company's stock, valued at approximately $72,000. PFG Investments LLC owned 0.12% of Tonix Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 82.26% of the company's stock.
About Tonix Pharmaceuticals
(
Get Free Report)
Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
Featured Articles
Before you consider Tonix Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tonix Pharmaceuticals wasn't on the list.
While Tonix Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
